[Timing of initiation of antiretroviral therapy in HIV-1-infected patients. Meta-analysis of the When To Start Consortium].
Goebel
F-D
FD
Medizinische Poliklinik der LMU, Pettenkoferstrasse 8a, 80336 München. fgoebel@med.uni-muenchen.de
Nitschmann
S
S
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods* / Q000592:standards; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D018450:Disease Progression; D004334:Drug Administration Schedule; D005060:Europe / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000635:transmission; D015497:HIV-1; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009656:North America / Q000453:epidemiology; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D016016:Proportional Hazards Models; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome
Optimaler Beginn der antiretroviralen Therapie bei HIV-positiven Patienten. Metaanalyse des When To Start Consortium.